Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abilify in bipolar depression
NCT03423680Phase 3Recruiting
- Sponsor
- Otsuka Holdings
- Start
- Feb 2018
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aripiprazole in bipolar disorder (BD), sponsored by Otsuka Holdings. Started Feb 2018; status: recruiting.
02
Drugs
aripiprazole
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03423680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03423680.